戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                 Analysis was by intention to treat.
2   The analysis was conducted by intention-to-treat.
3 ssion-free survival assessed by intention to treat.
4 ders, is highly prevalent but remains poorly treated.
5 , or with an osteoporotic BMD should also be treated.
6 derline rejections in protocol biopsies were treated.
7 essive clinical success has been observed in treating a variety of cancers using immunotherapy with p
8              Relative survival of electively treated AAA patients was stable and persistently comprom
9 nd the great adsorption efficiency of HNO(3)-treated ACFC.
10  regeneration efficiencies of raw and HNO(3)-treated activated carbon fiber cloth (ACFC) were examine
11     Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indic
12 hormone therapy remains a major challenge in treating advanced prostate cancer.
13 eplicates, and when the statistical analysis treats all data points as independent and thus fully con
14 lly administered BACE inhibitor developed to treat Alzheimer's disease.
15                                              Treating AML cells with an EZH2 inhibitor partially rest
16 4 years, which is equivalent to successfully treating an additional 91.1 (54.3, 127.3) gonorrhea case
17                              An intention-to-treat analysis revealed that the proportion of participa
18 ry endpoint was assessed in the intention-to-treat analysis set, after all participants completed the
19                          In the intention-to-treat analysis, there was no evidence of a difference in
20 ed participants in the modified intention-to-treat analysis, with 80 allocated to receive vitamin K a
21 osts of clinical and experimental studies to treat and understand heart function, respectively, in-si
22 iology, functional dyspepsia is difficult to treat and, in most patients, the condition is chronic an
23 s were treated with (177)Lu-DOTATATE or sham-treated and coinjected with (111)In-anti-gammaH2AX-TAT,
24 ted probability of uracil occurrence both in treated and non-treated cells.
25 f calcitriol on homeostatic (M-CSF, TGF-beta-treated) and proinflammatory (GM-CSF-treated) human mono
26  limited infrastructure to properly collect, treat, and deliver water.
27 gic agents that exploit or target TMPRSS6 to treat anemias and iron-related diseases.
28 cuss using first-line IV iron monotherapy to treat anemic patients with cancer, which decreases the n
29 ctivation occurred earlier in cyclosporine A-treated animals compared with those receiving rapamycin.
30             Moreover, the small intestine of treated animals show reduced hypoxic injury compared to
31 both the amoxicillin and ampicillin/neomycin treated animals.
32 nd 101 in slices from naive but not morphine-treated animals.
33 n granulomas and lymph nodes from anti-IL-10-treated animals.
34 d yet, no antivirals have been identified to treat astrovirus infection.
35                  We have studied 10 patients treated at 12 adult care hospitals.
36 llment of Medicare and non-Medicare patients treated at dialysis facilities before and after 2011 pay
37  large region because two thirds of patients treated at KHCC were non-Jordanians.
38 fail the chemoprophylaxis process measure if treated at nonsafety net hospitals (OR 0.62, 95% CI 0.39
39 survivors treated with ECMO, 32 who had been treated at the largest centre reported satisfactory Shor
40 ectly hint at an IVIg mechanism of action in treating autoimmune diseases and allosensitization by ac
41  high-grade osteosarcoma of the extremities, treated between 1980 and 2010.
42 repurposing an available drug to effectively treat both oral cancer metastasis and pain in a preclini
43 es demonstrate pitolisant to be effective in treating both hypersomnolence and cataplexy while genera
44 dimer selective inhibitors will be useful in treating BRAF-dependent tumors.
45 ma (GB) is a highly aggressive, difficult to treat brain tumour.
46 ths post-treatment, analysed by intention to treat by means of multilevel random effect regression an
47                        In addition, the must treated by UHPH keeps terpene concentrations similar to
48 erapy has emerged as a promising approach to treat cancer, however, its efficacy in highly malignant
49 ecently, bacteriocins have even been used to treat cancer.
50 of tumor-infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy.
51 f KRas, a protein implicated in difficult-to-treat cancers.
52 ike cell population that can be regulated to treat cardiac hypertrophy by improving neovascularizatio
53 ycle in PC3 cells, with the vast majority of treated cells in the G(2)/M phase (89%); 2) induces cell
54 of uracil occurrence both in treated and non-treated cells.
55  Total duration of therapy was determined by treating clinicians and the beta-lactam was administered
56                                For the early-treated cohort (83 HIV-1 adult patients treated within 3
57  has been the clinically adopted strategy to treat colorectal and breast cancers as well as age-relat
58 ments compared to green fluorescence protein-treated controls (1012 vg per animal, n = 10 per group)
59  of postnatal survival and growth to carrier-treated controls.
60 uine+/-azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a pauc
61 evelopment efforts aimed at intercepting and treating coronavirus disease 2019 (COVID-19) and help pr
62 ficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currentl
63 ous drugs that can be used to prevent and/or treat COVID-19.
64 e is no single intervention or medication to treat delirium, making it challenging to manage.
65 n depression and schizophrenia to be used to treat depression and psychotic symptoms in HD.
66 t MCT had considerable beneficial effects in treating depression that may exceed CBT.
67 rm clinical interventions to help prevent or treat disease.
68  address an unmet need for this difficult to treat disease.See related article by Gonda et al., p.
69 immune response, providing a new approach to treat diseases associated with endothelial dysfunction a
70 etween different tissues will be crucial for treating diseases in which type 2 immunity is an importa
71 n may represent a new therapeutic target for treating disordered energy metabolism metabolic syndrome
72 n = 20 out of 70, 29%), but less frequent in treated distant metastases (n = 9 out of 94, 10%).
73 that was similar to that in the participants treated during chronic infection.
74                                   Fingolimod-treated EAE mice were imaged with (18)F-FAC PET to asses
75                                          ABC-treated endothelial cells had higher levels of ICAM (int
76                Ruptured MCA aneurysms may be treated endovascularly with similar effects as unrupture
77 ent sunitinib treatment, tumors in sunitinib-treated EpsilonC-betaKO mice showed a marked decrease in
78                                           EV-treated ESCs continued to express stemness genes, preser
79 n of 6 to 15 mmHg as compared with nepafenac-treated eyes (6 eyes vs. 1 eye; P = 0.04); no eyes showe
80      Four weeks after LPI, more prednisolone-treated eyes showed IOP elevation of 6 to 15 mmHg as com
81                                  Aflibercept-treated eyes, which had borderline worse vision and thic
82 ts that, in young women, transseptal TMVI to treat failing bioprostheses may result in good short-ter
83 r inhibitor to the extent seen in ED peptide-treated female neurons.
84  after discharge among hospitalized patients treated for pneumonia or urinary tract infection (UTI) a
85            Whole blood samples from patients treated for symptomatic CAD including non-ST elevation M
86                            As a control, non-treated forced roots powder (FRP-BE) was tested.
87                  Apoptotic cell death of the treated HeLa and BE(2)-C cells was demonstrated by Annex
88 orbidity and mortality during antiretroviral-treated HIV disease.
89 ctional properties of infrared heat-moisture treated (HMT) maize meal with stearic acid were studied.
90  have emerged as a novel clinical therapy to treat homologous recombination-deficient tumors.
91 mekimab, previously found to be effective in treating HS, was evaluated using a subcutaneous formulat
92 t on HC, but conditioned supernatant of DMOG-treated HSC induced VEGF-dependent proliferation of LSEC
93 GF-beta-treated) and proinflammatory (GM-CSF-treated) human monocyte-derived macrophages and microgli
94 c leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behi
95                       Overall, 28 (20%) were treated in an emergency department, 1 (<1%) was hospital
96 eration in the study eye were randomized and treated in HAWK/HARRIER.
97      We present two cases of female patients treated in our department for duodenal diverticulum perf
98  629 participants were randomly assigned and treated in study 1 (314 to bictegravir, emtricitabine, a
99 % vs 53.9%; p < 0.0001), and more frequently treated in tertiary hospitals (74.7% vs 45.8%; p < 0.000
100                                      Animals treated in vivo with a mimic nanodrug had higher insulin
101 osed as one of the therapeutic strategies to treat individuals with metabolic syndrome, as RXR hetero
102  (1.24-log(10) reduction), which are used to treat infected PUs clinically.
103 that blocking of type 2 immune responses can treat infection.
104 profloxacin (CIP) is extensively employed to treat infections in animal and human medicine.
105 avir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections.
106                                 Intention-to-treat (ITT) and per-protocol (PP) analyses were undertak
107                 We analysed the intention-to-treat (ITT) population, adjusted for potential confounde
108                                 On intent-to-treat (ITT), the sCR rate reached 76%.
109  of allele-specific small interfering RNA in treating KID syndrome and other dominant genetic conditi
110 Ia results in enhanced ability to prevent or treat lethal viral respiratory infection in mice, with i
111                     Lithium has been used to treat major depressive disorder, yet the neural circuit
112 n brain synapses is a primary objective when treating major depressive disorder-a disease that afflic
113 as a safe and effective targeted approach to treating many types of cancer.
114 sonalized medicine strategies to effectively treat MDD.
115      In total, 212 patients in 35 sites were treated; mean (SD) baseline PASI score was 20.8 (7.68).
116 microscopy results showed void spaces on the treated melanin granules as compared to the untreated sa
117 ssion was reduced in the skin of doxycycline-treated MFS mice.
118   A complete response was attained in 60% of treated mice bearing 4T07 grafts.
119       The enhanced monocyte apoptosis in CMH-treated mice was paralleled by increased numbers of HIF-
120      Fewer varicosities developed in acutely treated mice while more varicosities resolved in mice wi
121 he decrease in tumor volumes observed in TCZ-treated mice, as well as a decrease in the CSC fraction.
122 r rechallenge in 33% of nanoformulated CCL21-treated mice.
123 el and were included in a modified intent-to-treat (mITT) analysis.
124 1-1.89, p = 0.04) versus neonates of insulin-treated mothers.
125 listin, an antibiotic of last resort used in treating multi-drug resistant bacterial infections in hu
126  shown activity in patients with heavily pre-treated multiple myeloma.
127 ), an FDA-approved immunomodulatory drug for treating multiple sclerosis, is an agonist of sphingosin
128  allogeneic, 30% autologous]; conventionally treated N = 1106) and noncancer controls (N = 242) from
129 l characteristics, the fate of the thermally treated nanomaterials may differ or not from the convent
130 d, increased bursts only in the specifically treated networks.
131  was killed more effectively in azithromycin-treated neutrophils, suggesting that pathogen-specific f
132    Patients (aged >=16 years) who were being treated non-operatively for a primary Achilles tendon ru
133                                   Anti-IL-10-treated nonhuman primates had similar overall disease ou
134 r alkaline fluids (hereafter referred to as "treated nontronites") under Mars-like surface conditions
135  to 1.00; p = 0.047) with a number needed to treat of 36 to prevent 1 death.
136  the effectiveness of current medications to treat opioid use disorder, there is still a high rate of
137 reaks but there are no approved therapies to treat or prevent CHIKV infection.
138                             Using antibiotic-treated or germ-free mice, we show that parathyroid horm
139 e of good design, durable woods and properly treated or modified woods will be paramount.
140 probiotics and prebiotics might be useful to treat oral halitosis.
141 uld still receive these agents to prevent or treat osteoporosis.
142 r suppressor pathways need to be explored to treat p53- deficient tumours.
143                               Corticosteroid-treated participants showed stunting of growth, whereas
144 ween bivalirudin (n=799) and heparin (n=793) treated patients >=75 years.
145 ted patients versus 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59-
146                             Among the 13 078 treated patients (mean [SD] age, 62.5 [9.0] years; 35% w
147 osite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl-treated
148  active at achieving deep remission for most treated patients with CLL, including those with high-ris
149 anti-PD-1 monoclonal antibody) in previously treated patients with HER2-positive gastro-oesophageal a
150 .004), respectively.Conclusions: Vasopressor-treated patients with shock are often exposed to a signi
151 oss the study groups revealed that anti-VEGF treated patients with wet AMD, who showed no exudative s
152 g term, it prolongs the survival time of the treated patients.
153 plies that future researchers and clinicians treating patients should quantify TME components, in par
154             Estrogen therapy is effective in treating patients with advanced BC after resistance to T
155                         Reports from centers treating patients with coronavirus disease 2019 (COVID-1
156  metabolism may be an effective approach for treating patients with PIK3CA-mutant colorectal cancers
157 r, turbidity reduction occurred up to 59% in treated pineapple juice with immobilized pectinase, sugg
158 rogression-free survival in the intention-to-treat population was 8.2 months (95% CI 6.5-8.3) in grou
159 50) at week 24, assessed in the intention-to-treat population.
160 ed events were also done in the intention-to-treat population.
161 al by independent review in the intention-to-treat population.
162 fit rate of 49% (22 of 45; 34-64) in the all-treated population, and 41% (14 of 34; 25-59) and 65% (2
163 ed in both endoperoxide- and tetrahydropyran-treated promastigotes.
164 ion therapy represent the major challenge in treating prostate cancer.
165 ple have not benefited equally from test-and-treat recommendations for HIV.
166 small molecules was shown to be promising in treating renal diseases.
167 hese detection strategies with presumptively treating residents of index households over a sustained
168                                         Heat-treated rice bran protected RP the best during forced st
169 PEF-1 CLE, compared to the control and other treated samples.
170                                   Of the 800 treated seeds, 415 germinated and were advanced up to fo
171 e the efficacy of an EBV-specific vaccine or treat severe EBV infection and pathological consequences
172 nted with recession at baseline but were not treated showed a significantly more apical shift of the
173 s AM may be an effective adjuvant therapy in treating sight-threatening infectious corneal ulcers by
174  ameliorating Treg function may be useful in treating skin inflammation in DOCK8 deficiency.
175 and may point to a new metabolic approach to treating some cancers.
176  treatment as a novel therapeutic avenue for treating T2DM.
177 ers may have the potential to prevent and to treat the acute lung injury after SARS-CoV-2 infection,
178                Reinforcement learning models treat the basal ganglia (BG) as an actor-critic network.
179 neral dental practitioner, who is advised to treat the child as being at high caries risk.
180  design of network-correcting therapies that treat the core disease mechanism.
181                                           To treat the deficit arising from Chrna5 disruption without
182    Most physicians indicated that they would treat the patients themselves with a focus on managing I
183 is, therefore, critical to understanding and treating the disease.
184 e carrier family 25 member 46 (Slc25a46) and treated them with neurotrophic AAV-PHP.B vector carrying
185                                We found that treating these cells with laminin causes endogenous agri
186 est a paradigm for classifying, staging, and treating these diseases.
187 expedited effort to understand, prevent, and treat this disease.
188 ciated with shorter survival in chemotherapy-treated TNBC patients.
189 ce visits and enable improved application of treat-to-target strategies.
190                  Repurposing of ketamine for treating TRD provided a new understanding of the pathoph
191 variously designated as having 'difficult to treat', 'treatment-resistant' or 'refractory' RA.
192 he frequency of ICAM-1(+) BMDN, while rmCIRP-treated TREM-1(-/-) BMDN or pretreatment of BMDN with TR
193 howed stunting of growth, whereas vamorolone-treated trial participants did not (p < 0.001; LS mean 1
194     No effective therapy is yet available to treat triple negative breast cancer (TNBC), which has po
195                                Patients were treated two to three times per week with high-frequency
196 n of antibiotics has proved disappointing in treating UTI, likely due to the failure of infused antib
197 enolytics, have the potential to prevent and treat various age-related diseases and extend healthspan
198 ipase A2 (PLA2) has long been considered for treating various diseases associated with an elevated PL
199 ular angioplasty with a retrievable stent to treat vasospasm related to SAH due to an aneurysm in fou
200           AL growth was analyzed relative to treated vs fellow eye, contact lens (CL) vs intraocular
201 ruginosa isolates susceptible to TOL-TAZ and treated with >=72 hours of TOL-TAZ between January 2018
202 atin receptor-positive tumor xenografts were treated with (177)Lu-DOTATATE or sham-treated and coinje
203 y, including 34 nonirradiated male survivors treated with 0 < CED < 4,000 mg/m(2) (P = 3.1 x 10(-4))
204 4 patients with exudative AMD were initially treated with 3 monthly IAI and thereafter as-needed IAI
205                               Spheroids were treated with 5-Fluorouracil for five days through contin
206 as considered as one group, and the same eye treated with a different medication during the observati
207 to the eye and the medication so that an eye treated with a particular medication was considered as o
208 <0.01), and the percent of eligible patients treated with alteplase increased by 8% (P=0.03).
209  by 1.8 minutes (P=0.02), number of patients treated with alteplase was an additional 1.7 (P<0.01), a
210  aminonucleoside (PAN) nephropathy rat model treated with amiloride, an inhibitor of plasminogen acti
211                               NF2-null cells treated with an ERBB3-neutralizing antibody partially do
212 e or severe ischemia on stress testing to be treated with an initial invasive strategy consisting of
213 ies performed in mice fed with cuprizone and treated with anacardic acid showed lower g-ratio scores
214 subset analysis of vaccinated patients newly treated with anti-programmed cell death protein 1 (PD-1)
215     C57BL/6J female mice (n = 18) were first treated with antibiotics for 4 weeks to ablate the micro
216 eks to 3 months after IE diagnosis, patients treated with anticoagulative therapy had a lower risk of
217 nty-seven patients with low CrAg titers were treated with antifungal therapy and 22 (81%) responded w
218 ding those with SPINK1-positive subtype, are treated with AR-antagonists.
219 ence of aspirin resistance than all patients treated with aspirin alone and TCT decreased the frequen
220 L-8 exhibited improved overall survival when treated with atezolizumab but not with chemotherapy.
221  7 medical centers in the United States were treated with axi-cel and were included in a modified int
222  more in physiologically relevant conditions treated with AZM, likely due to general changes in cell
223 wer graft survival in CMV high-risk patients treated with belatacept and whether it is explained by t
224                            All patients were treated with biguanides and/or diamidines or azoles with
225   Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence
226 (2) (P = 3.1 x 10(-4)) and 24 male survivors treated with CED >=4,000 mg/m(2) and radiotherapy <40 Gr
227 actors in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy, but are less well studi
228                        Hospitalized patients treated with chloroquine/hydroxychloroquine+/-azithromyc
229 or patients with haematological malignancies treated with chronically administered therapies.
230 eactors inoculated with healthy human feces, treated with clindamycin and infected with C difficile w
231                         In phase 2, patients treated with combination therapy achieved an overall res
232 nin virus infection, a related virus, can be treated with convalescent-phase serum.
233 e disease with extremely poor prognosis when treated with conventional chemotherapy.
234                         Patients (2013-2018) treated with curative intent by open surgery were studie
235        Patients >=18 years of age with PMBCL treated with curative intent rituximab-chemotherapy were
236                         Jude Lifetime Cohort treated with cyclophosphamide equivalent dose (CED) >=4,
237 afety study to describe outcomes in children treated with dabigatran etexilate for secondary venous t
238                            All patients were treated with definitive chemoradiation (median dose 50.4
239 he jaw occurred in 122 (5%) of 2241 patients treated with denosumab versus four (<1%) of 2218 patient
240                       Among the 49 survivors treated with ECMO, 32 who had been treated at the larges
241 were also significantly enhanced in patients treated with ECMO.
242                 Most patients with SMPE were treated with embolectomy (98.9% [91 of 92]), while ECMO
243 ve heart failure rat (mRen27/tetO-shIR) were treated with empagliflozin (10 mg/kg/d) or vehicle for 4
244                            All patients were treated with gemcitabine and S-1 (GS)-based chemotherapi
245 drenal dysfunction or severe asthma that are treated with high doses of inhaled corticosteroids.
246 enting with cavitary retinoblastoma who were treated with IAC.
247 L-6 blockade attenuates disease only in mice treated with IFN-I.
248 cally confirmed stage IIIB-IV NSCLC who were treated with immune checkpoint blockade between June 201
249 accine exacerbates immune events in patients treated with immune checkpoint inhibitors (ICIs).
250  renal carcinomas (n=11), or melanoma (n=44) treated with immunotherapy.
251                                     Patients treated with intra-arrest transport (exposed) were match
252                     Cdkl5 knockout male mice treated with isoform 1 via intrajugular injection at age
253 eated with IVF (27.3%) compared to those not treated with IVF (26.9%) during their entire ETU admissi
254 cant difference in 28-day survival for cases treated with IVF (27.3%) compared to those not treated w
255 cytes harvested from knees of rats with PTOA treated with liposomal A2AR agonist revealed downregulat
256                     QOL improved in patients treated with LS + inulin compared with placebo (P = 0.02
257  with oral vancomycin were compared to those treated with metronidazole after balancing on patient ch
258   After up to 6 years of follow-up, patients treated with mite allergoid required significantly fewer
259 s with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled
260                     In the liver of the mice treated with OCA, the levels of cytochrome P450 potentia
261 n rate >=25 to <75 mL per min per 1.73 m(2), treated with optimized renin-angiotensin system blockade
262                                     Patients treated with oral vancomycin were compared to those trea
263 ry care patients with influenza-like illness treated with oseltamivir recovered one day sooner on ave
264 akic rhegmatogenous retinal detachment (RRD) treated with pars plana vitrectomy (PPV) or PPV with scl
265          Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1
266              Here, we demonstrate that cells treated with pharmaceutical-grade rigosertib (>99.9% pur
267 denosumab versus four (<1%) of 2218 patients treated with placebo; treatment-emergent hypocalcaemia o
268                                         Mice treated with PLX5622 had a significantly faster decrease
269 ble differences in outcomes between patients treated with polymer-free versus durable polymer DES.
270 eudophakic RRDs, SSAS was better in patients treated with PPV-SB compared with PPV alone, whereas vis
271   Intraocular medulloepithelioma is commonly treated with primary enucleation.
272 posed as a potential risk factor in patients treated with RAAS inhibitors.
273 ed 53 patients with hepatocellular carcinoma treated with radioembolization at our center.
274 ) and survival in patients with lung cancer, treated with radiotherapy.
275 to IV DAWT compared with historical controls treated with regimen I.
276 ymphocytic leukaemia have poor outcomes when treated with regimens that do not contain a tyrosine-kin
277 he intravascular space was increased in rats treated with rTM although the statistical power for this
278 lating lipotoxicity in skeletal muscle cells treated with saturated FA, palmitate.
279 mpares moderately complex phakic primary RRD treated with SB, PPV, or PPV/SB to review anatomic and v
280  patients with posterior circulation strokes treated with stent-retrievers at our center between Dece
281 better disease-specific survival in patients treated with surgery alone.
282                                    Melanomas treated with the 10-mm plaque were smaller (median thick
283 veola (median, 2.0 mm vs. 2.8 mm) than those treated with the 15-mm plaque (P < 0.001).
284                However, C57BL/6J female mice treated with the benzimidazole inhibitor exhibited a sig
285                                     Patients treated with the best-performing arm, C-MTX plus nelarab
286                                 Rabbits were treated with the beta3 AR agonists CL316,243 or ASP9531,
287                                 Caco-2 cells treated with the chelate at calcium concentrations of 0-
288 RA+], C1q+) heart transplant candidates were treated with the combination of belatacept and PI therap
289 recovery of hematopoietic components in mice treated with the endoradiotherapeutic agent (153)Sm-EDTM
290 ishment of autoimmune myocarditis, mice were treated with the immunoproteasome inhibitor ONX 0914.
291 n patients with acute myeloid leukemia (AML) treated with the isocitrate dehydrogenase 2 (IDH2) mutan
292                          Group 2 (n=30) were treated with the same schedule and had sparse dolutegrav
293 sponse for two HER2 + breast cancer patients treated with the same therapeutic regimen but who achiev
294                  We also used wild-type mice treated with the SULT1E1 inhibitor triclosan to determin
295 patients who were removed from the study and treated with topical corticosteroids according to best m
296 rsistent epithelial defect or corneal ulcer, treated with topical rhNGF, and age-matched healthy cont
297 positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab em
298                       Transplanted mice were treated with vehicle or di-n-butyl-phthalate (DBP, a pla
299 arly-treated cohort (83 HIV-1 adult patients treated within 3 months after infection), HIV-1 diagnosi
300 and necessitates consideration by clinicians treating women with diverse life histories.

 
Page Top